GNMSFvs its industry peers
A metric-by-metric comparison of GNMSF against SIC 2834 — valuation, growth, profitability, quality and total return, with each figure's rank within the peer group. Every value is Go-computed from SEC filings and delayed prices; ranks are sorted positions within the group only — descriptive, not advice.
| Empresa | Market cap | P/E (TTM) | P/B | P/S | Revenue growth (YoY) | Earnings growth (YoY) | EBIT margin | ROE | ROIC | Piotroski F | 1y total return | Dividend yield |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| GNMSFEsta | — | — | — | — | 19.2%#1 | -15.0%#3 | 28.6%#1 | — | — | — | — | — |
| GLMD | $30M#5 | — | 2.4x#2 | — | — | -37.1%#5 | — | -80.9%#3 | — | — | — | — |
| GMAB | — | — | — | — | 19.2%#1 | -15.0%#3 | 28.6%#1 | — | — | — | 23.0%#1 | — |
| GRCE | $45M#4 | — | 0.9x#1 | 0.5x#1 | — | 18.6%#2 | -11.1%#4 | -16.2%#2 | — | — | -30.4%#2 | — |
| GSK | $220.4B#1 | — | — | — | — | — | — | — | — | — | — | — |
| HCM | $12.1B#2 | 26.6x#1 | 9.8x#3 | 22.0x#2 | -13.0%#3 | 1111.0%#1 | -7.1%#3 | 36.9%#1 | 0.0%#1 | — | — | — |
| HELP | $303M#3 | — | — | — | — | — | — | — | — | — | — | — |
Peer set: US filers sharing this company's SEC industry classification (SIC 2834). SIC is coarse — conglomerates and multi-segment companies map imperfectly. Values from SEC filings + delayed prices; ranks are within-group positions only. Market cap, P/E, P/B, P/S, 1y total return and dividend yield are computed from each member's latest snapshot price when the table is built (see as-of; snapshot prices can lag) — not live. Some peers are still being computed, so this table covers part of the group and ranks are within the rows shown; it fills in shortly. Esta tabla agotó el tiempo durante su construcción, por lo que cubre parte del grupo; los rangos son solo dentro de las filas mostradas y se completará en breve. Table built 2026-09-17.
Source: SEC XBRL filings + delayed prices · ranks are within-group positions · For reference only · Not investment advice